Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.04, read 2026-10-28
Ethical passes the values gate
Price239.34 USD
Fair value285.56
Ethical score70.0/100
Our investment reviews on this name
2026-10-18Read Distribution238.71+0.3% to today Markup gives way to Distribution after a 12% slide in 7 days
2026-10-11Read Markup270.27-11.4% to today Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation270.27-11.4% to today Distribution gives way to Accumulation after a 12% rise in 3 weeks
2026-09-09Read Distribution240.94-0.7% to today ✓Markup gives way to Distribution after an 18% slide in 10 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Plexus Corp. holds its Distribution at $239.34. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-10-28
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$239.34
Valuation
34.92 trailing · 23.36 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.89
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.33%
Below 33%
Interest-bearing debt is just 5.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
30.70%
Below 49%
Money owed to the company is 30.7% of assets, under the 49% limit.
Pass
Revenue purity
0.10%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Plexus clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 5%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PLXS's ethical verdict changes
Today PLXS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 19.3% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +29% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Electronics assembler with slim safety margin
Picture the circuit boards inside medical gear or industrial machines. Someone has to design, source and build them at scale. Plexus does exactly that across the US, Asia and Europe, and it is growing revenue 19 percent a year while clearing a thin 4 percent profit margin.
We pass because the numbers do not add up to an edge. At 26.5 times forward earnings the shares already price in decent growth, yet the margin of safety is just 8 percent and return on equity sits at only 13 percent with no clear moat. Analyst targets around 292 dollars offer little extra room once normal volatility hits.
Low margins leave little cushion if component costs rise or customers push back on pricing. Unknown competitive durability adds further uncertainty even though the ethical screen is clear. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PLXS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Distribution$236.44+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Distribution$236.44+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$236.44+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$236.44+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$236.44+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$236.44+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$236.44+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$236.44-1.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter.
2026-10-11Markup · changed$270.27+0.0%Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (4 analysts) rates it buy, with a mean price target of $274. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
